Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicentre, prospective, real-world cohort study assessing the impact of Selexipag and other Pulmonary Arterial Hypertension (Pah) Therapies and its safety profile

Next Previous
Trial Profile

A multicentre, prospective, real-world cohort study assessing the impact of Selexipag and other Pulmonary Arterial Hypertension (Pah) Therapies and its safety profile

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 08 Oct 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Selexipag (Primary) ; Antihypertensives
  • Indications Pulmonary arterial hypertension
  • Focus Adverse reactions
  • Acronyms EXPOSURE

Most Recent Events

  • 29 Aug 2022 Results (n=382; as of Nov 2020) reporting outcomes during selexipag exposure method presented at the ESC Congress 2022 - Annual Congress of the European Society of Cardiology
  • 29 Aug 2022 Results (n=1588; Between September 2017 and November 2021) assessing the clinical characteristics, treatment patterns and outcomes of pulmonary arterial hypertension associated with congenital heart disease patients in current clinical practice, presented at the ESC Congress 2022 - Annual Congress of the European Society of Cardiology.
  • 19 May 2021 Results (Data cut off date June 2020, n=300) of EXPOSURE observational study assessing Selexipag Titration and Dosing Patterns in Patients with Pulmonary Arterial Hypertension (PAH) presented at the 117th International Conference of the American Thoracic Society

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top